natgillin/translations-raw huggingface dataset:
Glycerol Phenol Metacresol Zinkchlorid
Glycerol Phenol Metacresol Zinc chloride
Glycerol Phenol Zinkacetat
Glycerol Phenol Zinc acetate
Glycerol Renset vand
Glycerol Purified water
Glycerol Titandioxid Propylenglycol Natriumhydroxid Renset vand
Glycerol Titanium dioxide Propylene glycol Sodium hydroxide Purified water
Glycerol, metacresol, phenol, natriumchlorid, zinkacetat, saltsyre/natriumhydroxid (til pH-justering) og vand til injektionsvæsker
Glycerol, metacresol, phenol, sodium chloride, zinc acetate, hydrochloric acid and sodium hydroxide (for pH adjustment) and water for injections
glycerol, phenol, metacresol, zinkacetat, dinatriumphosphatdihydrat, natriumchlorid, saltsyre/natriumhydroxid til justering af pH og vand til injektionsvæsker
glycerol, phenol, metacresol, zinc acetate, disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide for pH adjustment and water for injections
glycerol, phenol, metacresol, zinkchlorid, dinatriumphosphatdihydrat, natriumchlorid, protaminsulfat, saltsyre/natriumhydroxid til pH justering og vand til injektionsvæsker
glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, protamine sulfate, hydrochloric acid/sodium hydroxide for pH adjustment and water for injections
glycerol, phenol, metacresol, zinkchlorid, dinatriumphosphatdihydrat, natriumchlorid, saltsyre/natriumhydroxid til justering af pH og vand til injektionsvæsker
glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide for pH adjustment and water for injections
glycerol, phenol, metacresol, zinkchlorid, dinatriumphosphatdihydrat, natriumchlorid, saltsyre/natriumhydroxid til justering af pH og vand til injektionsvæsker
glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide for pH adjustment and water for injections.
glycerol, phenol, metacresol, zinkchlorid, dinatriumphosphatdihydrat, natriumchlorid, saltsyre/natriumhydroxid til justering af pH og vand til injektionsvæsker.
glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide for pH adjustment and water for injections
glycerol, phenol, metacresol, zinkchlorid, dinatriumphosphatdihydrat, natriumchlorid, saltsyre/natriumhydroxid til justering af pH og vand til injektionsvæsker.
glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide for pH adjustment and water for injections.
Glycerolmonostearat 40-55, hyprolose,
Glycerol monostearate 40-55, hyprolose,
Glycerolphenylbutyrat
Glycerol phenylbutyrate
glyceryltrinitrat (nitroglycerin) og andre nitrater eller andre stoffer, som kaldes ”vasodilatorer” (mod hjertekramper/angina pectoris);
nitroglycerin and other nitrates, or other substances called “vasodilators”;
Glycin Glutaminsyre Natriumchlorid Polysorbat 80 Natriumhydroxid
Sodium chloride Polysorbate 80 Sodium hydroxide
Glycin Macrogol 300
Glycine Macrogol 300
Glycin Natriumchlorid Natriumcitrat Calciumchlorid Humant albumin Mannitol Natriumacetat
Sodium chloride Sodium citrate Calcium chloride Human albumin Mannitol Sodium acetate
Glycin,
Glycine,
Glycin, natriumchlorid, kalciumchlorid, histidin, polysorbat 80, saccharose.
Glycine, sodium chloride, calcium chloride, histidine, polysorbate 80, sucrose.
Glycoengineering af Fc-delen af obinutuzumab giver højere affinitet for FcɣRIII-receptorerne på immune effektorceller som naturlige dræberceller, makrofager og monocytter sammenlignet med non- glycoengineered antistoffer.
Glycoengineering of the Fc part of obinutuzumab results in higher affinity for FcɣRIII receptors on immune effector cells such as natural killer (NK) cells, macrophages and monocytes as compared to non- glycoengineered antibodies.
Glycoproteïne IIb/IIIa-remmers: clopidogrel dient met voorzichtigheid te worden gebruikt bij patiënten die gelijktijdig glycoproteïne IIb/IIIa-remmers krijgen (zie rubriek 4.4).
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
glykosuri, proteinuri
Glycosuria, proteinuria
Glykæmisk kontrol
Metformin
Glykæmisk kontrol Monoterapi
Glycaemic control Monotherapy
Glykæmisk kontrol skal nøje vurderes, når saxagliptin anvendes samtidig med en potent CYP3A4- inducer.
Glycaemic control should be carefully assessed when saxagliptin is used concomitantly with a potent CYP3A4/5 inducer.
GM-CSF, n = 55)
GM-CSF, n = 86)
GMC før boostervaccinationen (8-12 måneder efter sidste primærdosis) var generelt sammenlignelige for de to vacciner.
Pre-booster GMCs (8 to 12 months after the last primary dose) were generally similar for the two vaccines.
gMean (gCV %; range) halveringstid
gMean (gCV %; range) half-life
gMean (gCV %; range) halveringstid
gMean (gCV%; range) half-life
GMR (%) (90% CI)
GMR (%) (90%CI)
GMR (95 % CI)
GMR (95% CI)
GMT (95 % CI)
GMT (95%CI)
GMT (95 %-CI)
GMT (95% CI)
GMT (95 %CI)
GMT (95%CI)
GMT [95 % CI] (N)
GMT [95% CI] (N)
GMT hos disse forsøgspersoner var 16,2 (95 % CI: 13,8; 19,0) efter 24 måneder.
GMT in these subjects was 16.2 (95% CI: 13.8, 19.0) at Month 24.
GMT'er var højere for piger og drenge end for kvinder på mellem 16 og 26 år, og højere for drenge end for piger og kvinder.
GMTs were higher in girls and boys than in 16- through 26-year-old women, and higher in boys than in girls and women.
GMT'erne over for HPV-type 6, 11, 16 og 18 var højere end i den population, som ikke tidligere havde fået qHPV-vaccinen i andre studier, hvorimod GMT'erne over for HPV-type 31, 33, 45, 52 og 58 var lavere.
The GMTs to HPV Types 6, 11, 16, 18 were higher than in the population who had not previously received qHPV vaccine in other studies whereas the GMTs to HPV Types 31, 33, 45, 52 and 58 were lower.
GMT=Geometriske middeltitre.
GMT=Geometric Mean Titers.
GMT=Geometriske middeltitre. cLIA= Kompetitiv Luminex-baseret immunanalyse.
GMT=Geometric Mean Titers. cLIA= Competitive Luminex Immunoassay.
GMTer for HPV-6, -11, -16 og -18 var numerisk sammenlignelige hos forsøgspersoner, som modtog qHPV-vaccine eller Gardasil 9 i mindst 3,5 år.
GMTs for HPV-6, -11, -16 and -18 were numerically comparable in subjects who received qHPV vaccine or Gardasil 9 for at least 3.5 years.
Gnid forsigtigt cremen ind i området, indtil cremen ikke ses længere.
Rub gently into the skin until the cream vanishes.
Gnid ikke huden på injektionsstedet.
Do not rub the skin at the injection site.
Gnid ikke injektionsstedet med snavsede hænder eller en snavset klud.
Do not rub the injection site with dirty hand or cloth.
Gnid ikke på hudområdet
Do not rub the area.
Gnid ikke på hudområdet.
Do not rub the area.
Gnid ikke på ind- stiksstedet.
Do not rub the area you have just injected.
Gnid ikke på indsprøjtningsstedet.
Do not rub the injection area.
Gnid ikke på indstiks- stedet.
Do not rub the area you have just injected.
Gnid ikke på indstiksstedet.
Do not rub the area you have just injected.
Gnid ikke på injektionsstedet
Do not rub
Gnidningen vil ikke fjerne ikke- opløste sårskorper, der sidder fast i områder, hvor der stadig er sårskorper tilbage.
Rubbing will not remove adhering undissolved eschar in areas where the eschar still remains.
GnRF (Gonadotropin releasing factor)-analog-proteinkonjugat min.
Gonadotropin releasing factor (GnRF) analogue-protein conjugate min.
GnRF analog-protein konjugat min.
GnRF analogue-protein conjugate min.
GnRF analog-proteinkonjugat min.
GnRF analogue-protein conjugate min.
GnRF er ansvarlig for opretholdelsen af testikelfunktionen hos hangrise.
GnRF is responsible for maintaining the activity of the testicles in male pig.
GnRF – analog – proteinkonjugat: Zoetis Belgium SA
GnRF analogue-protein conjugate: Zoetis Belgium SA
GnRH analoger er peptider.
GnRH analogues are peptides.
GnRH regulerer udskillelsen af gonadotropiner (luteiniserende hormon (LH) og follikelstimulerende hormon (FSH).
GnRH regulates the release of gonadotrophins (luteinising hormone (LH) and follicle stimulating hormone (FSH)).
Gnsn. ± SD
Mean ± SD
Gnsn. ± SD
Mean± SD
Gnsnt.
Mean
God behandlings- og hygiejnepraksis bør følges for at reducere risikoen for re-infektion.
Good management and hygiene practices should be introduced in order to reduce the risk of re- infection.
God behandlings- og hygiejnepraksis bør følges for at reducere risikoen for re-infektion.
Good management and hygiene practices should be introduced to reduce the risk of re-infection.
God behandlings- og hygiejnepraksis bør følges for at reducere risikoen for reinfektion.
Good management and hygiene practices should be followed to reduce the risk of re-infection.
God-, ondartede og uspecificerede neoplasmer (inklusiv cyster og polypper)
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Godartede cyster
Benign cysts
godartede cyster en alvorlig, reversibel tilstand i hjernen, der omfatter krampeanfald, højt blodtryk, hovedpine, træthed, konfusion, blindhed eller andre synsproblemer.
benign cysts a severe reversible brain condition which includes seizures, high blood pressure, headaches, tiredness, confusion, blindness or other vision problems.
godartede svulster
benign tumours
Godartede svulster i brysterne eller leveren, der ikke skyldes kræft
Non-cancerous (benign) tumours in your breast or liver
godartede svulster;
benign tumours;
Godartede, ondartede og neoplasmer (herunder cyster og polypper)
Neoplasms, benign, malignant and unspecified (incl. cysts and polyps)
Godartede, ondartede og uspecificerede svulster (herunder cyster og polypper)
Neoplasms benign and malignant (including
Godartede, ondartede og uspecificerede svulster (herunder cyster og polypper):
Neoplasms benign and malignant:
Gode injektionssteder er øverste del af låret og omkring maven, men væk fra navlen.
Good injection sites are the top of the thigh and around the tummy (abdomen) but away from the navel.
Gode steder er den øverste del af låret og på maven, men ikke nær navlen.
Good sites are the top of the thigh and around the tummy (abdomen) but away from the navel.
Gode steder til injektionen er øverste del af låret eller omkring maven (abdomen) mindst 5 cm fra navlen.
Good places for the injection are the upper thigh or around the belly (abdomen) at least 5 cm away from the navel (belly button)
Gode sårplejeforanstaltninger omfatter:
Good wound care measures include:
Godkendt dosering til patienter, som skal have foretaget perkutan koronar intervention (PCI): Det autoriserede og godkendte Angiox-dosisregime er en intravenøs bolusinjektion på 0,75 mg/kg legemsvægt straks efterfulgt af intravenøs infusion af 1,75 mg/kg/time som minimum under hele PCI-proceduren.
Approved dose in patients undergoing percutaneous coronary intervention (PCI): The licensed and approved dosing regimen of Angiox is an intravenous (IV) bolus injection of 0.75 mg/kg body weight followed immediately by an intravenous infusion at 1.75 mg/kg/hour for at least the duration of the PCI.
Godkendt koppevaccine
Licensed smallpox vaccine
Godkendt tilsætningsstof (E 260), CR nr.
Approved food additive (E 260), CR No 2034/96
Godkendt tilsætningsstof (E 262), CR nr.
Approved food additive (E 262), CR No 2034/96
Godkendt tilsætningsstof (E 524), CR nr.
Approved food additive (E 524), CR No 2034/96
GOG-0218 var et fase III, multicenter, randomiseret, dobbeltblindet, placebokontrolleret, tre-armet studie, som evaluerede effekten af tillæg af Avastin til et godkendt kemoterapiregime (carboplatin og paclitacxel) hos patienter med fremskreden (FIGO-stadie III B, III C og IV) epitelial ovariecancer, tubacancer eller primær peritonealcancer.
The GOG-0218 study was a phase III multicentre, randomised, double-blind, placebo-controlled, three arm study evaluating the effect of adding Avastin to an approved chemotherapy regimen (carboplatin and paclitaxel) in patients with advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube or primary peritoneal cancer.
Golimumab er opbygget, så det bindes til og blokerer et af kroppens kemiske signalstoffer kaldet tumornekrosefaktor alpha (TNF-).
Golimumab has been designed to attach to and block a chemical messenger in the body called tumour necrosis factor alpha (TNF-).
Gonademisdannelse, der er uforenelig med graviditet
Malformations of sexual organs incompatible with pregnancy
Gonadotropin releasing factor (GnRF) analog-protein konjugat min.
Gonadotropin releasing factor (GnRF) analogue-protein conjugate min.
Gonadotropin releasing factor (GnRF) analog-proteinkonjugat min.
Gonadotropin releasing factor (GnRF) analogue-protein conjugate min.
gonal-f 1.050 ie
gonal-f 1050 iu
GONAL-f 1.050 IE/1,75 ml (77 mikrogram/1,75 ml) pulver og solvens til injektionsvæske, opløsning
GONAL-f 1050 IU/1.75 mL (77 micrograms/1.75 mL) powder and solvent for solution for injection
GONAL-f 1.050 IE/1,75 ml (77 mikrogram/1,75 ml) pulver og solvens til injektionsvæske, opløsning
GONAL-f 1050 IU/1.75 mL (77 micrograms/1.75 mL) powder and solvent for solution for injection.
GONAL-f 1.050 IE/1,75 ml (77 mikrogram/1,75 ml), ETIKET TIL HÆTTEGLAS
GONAL-f 1050 IU/1.75 ML (77 MICROGRAMS/1.75 ML), VIAL LABEL
gonal-f 300 ie
gonal-f 300 iu
gonal-f 300 ie/0,5 ml
gonal-f 300 iu/0.5 mL
GONAL-f 300 IE/0,5 ml (22 mikrogram/0,5 ml) injektionsvæske, opløsning i fyldt pen
GONAL-f 300 IU/0.5 mL (22 micrograms/0.5 mL) solution for injection in a pre-filled pen
GONAL-f 300 IE/0,5 ml (22 mikrogram/0,5 ml) injektionsvæske, opløsning i fyldt pen
GONAL-f 300 IU/0.5 mL (22 micrograms/0.5 mL) solution for injection in pre-filled pen.
GONAL-f 300 IE/0,5 ml (22 mikrogram/0,5 ml), PEN, PENETIKET
GONAL-f 300 IU/0.5 ML (22 MICROGRAMS/0.5 ML) PEN, PEN LABEL
GONAL-f 300 IE/0,50 ml (22 mikrogram/0,50 ml) pulver og solvens til injektionsvæske, opløsning
GONAL-f 300 IU/0.50 mL (22 micrograms/0.50 mL) powder and solvent for solution for injection
GONAL-f 300 IE/0,50 ml (22 mikrogram/0,50 ml) pulver og solvens til injektionsvæske, opløsning
GONAL-f 300 IU/0.50 mL (22 micrograms/0.50 mL) powder and solvent for solution for injection.
GONAL-f 300 IE/0,50 ML (22 MIKROGRAM/0,50 ML), ETIKET TIL HÆTTEGLAS
GONAL-f 300 IU/0.50 ML(22 MICROGRAMS/0.50 ML), VIAL LABEL
GONAL-f 300 IE/0,50 ml, pulver til injektionsvæske, opløsning Follitropin alfa s.c.
GONAL-f 300 IU/0.50 mL powder for solution for injection Follitropin alfa
gonal-f 450 ie
gonal-f 450 iu
GONAL-f 450 IE/0,75 ml
GONAL-f 450 IU/0.75 mL
GONAL-f 450 IE/0,75 ml (33 mikrogram/0,75 ml) injektionsvæske, opløsning i fyldt pen
GONAL-f 450 IU/0.75 mL (33 micrograms/0.75 mL) solution for injection in a pre-filled pen
GONAL-f 450 IE/0,75 ml (33 mikrogram/0,75 ml) injektionsvæske, opløsning i fyldt pen
GONAL-f 450 IU/0.75 mL (33 micrograms/0.75 mL) solution for injection in pre-filled pen.
GONAL-f 450 IE/0,75 ml (33 mikrogram/0,75 ml) pulver og solvens til injektionsvæske, opløsning
GONAL-f 450 IU/0.75 mL (33 micrograms/0.75 mL) powder and solvent for solution for injection
GONAL-f 450 IE/0,75 ml (33 mikrogram/0,75 ml) pulver og solvens til injektionsvæske, opløsning
GONAL-f 450 IU/0.75 mL (33 micrograms/0.75 mL) powder and solvent for solution for injection.
GONAL-f 450 IE/0,75 ML (33 MIKROGRAM/0,75 ML), ETIKET TIL HÆTTEGLAS
GONAL-f 450 IU/0.75 ML (33 MICROGRAMS/0.75 ML), VIAL LABEL
GONAL-f 450 IE/0,75 ml (33 mikrogram/0,75 ml), PEN, PENETIKET
GONAL-f 450 IU/0.75 ML (33 MICROGRAMS/0.75 ML) PEN, PEN LABEL
GONAL-f 450 IE/0,75 ml, pulver til injektionsvæske, opløsning Follitropin alfa s.c.
GONAL-f 450 IU/0.75 mL powder for solution for injection Follitropin alfa
gonal-f 75 ie
gonal-f 75 iu
GONAL-f 75 IE (5,5 MIKROGRAM) ETIKET TIL HÆTTEGLAS
GONAL-f 75 IU (5.5 MICROGRAMS) VIAL LABEL
GONAL-f 75 IE (5,5 mikrogram) pulver og solvens til injektionsvæske, opløsning
GONAL-f 75 IU (5.5 micrograms) powder and solvent for solution for injection
GONAL-f 75 IE (5,5 mikrogram), pulver og solvens til injektionsvæske, opløsning
GONAL-f 75 IU (5.5 micrograms) powder and solvent for solution for injection.
GONAL-f 75 IE (5,5 g), pulver til injektionsvæske, opløsning Follitropin alfa s.c.
GONAL-f 75 IU (5.5 μg) powder for solution for injection Follitropin alfa
GONAL-f 900 IE/1,5 ml
GONAL-f 900 IU/1.5 mL
GONAL-f 900 IE/1,5 ml (66 mikrogram/1,5 ml) injektionsvæske, opløsning i fyldt pen
GONAL-f 900 IU/1.5 mL (66 micrograms/1.5 mL) solution for injection in a pre-filled pen
GONAL-f 900 IE/1,5 ml (66 mikrogram/1,5 ml), PEN, PENETIKET
GONAL-f 900 IU/1.5 ML (66 MICROGRAMS/1.5 ML) PEN, PEN LABEL
GONAL-f 900 IE/1.5 ml (66 mikrogram/1,5 ml) injektionsvæske, opløsning i fyldt pen
GONAL-f 900 IU/1.5 mL (66 micrograms/1.5 mL) solution for injection in pre-filled pen.
GONAL-f bliver leveret som pulver og solvens til injektionsvæske, opløsning.
GONAL f is presented as a powder and solvent for injection.
GONAL-f er beregnet til indsprøjtning under huden (subkutant).
GONAL-f is intended to be given by injection just under the skin (subcutaneously).
GONAL-f er et potent gonadotropinprodukt som kan fremkalde milde til alvorlige bivirkninger, og bør derfor kun bruges af læger som er specialiseret i infertilitetsbehandling.
GONAL-f is a potent gonadotrophic substance capable of causing mild to severe adverse reactions, and should only be used by physicians who are thoroughly familiar with infertility problems and their management.
GONAL-f er ikke beregnet til brug hos børn.
GONAL-f is not indicated for use in children.
GONAL-f er indiceret til stimulation af spermatogenesen hos mænd, som har medfødt eller erhvervet hypogonadotrop hypogonadisme i kombination med behandling med humant choriongonadotropin (hCG).
GONAL-f is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotropin (hCG) therapy.
GONAL-f gives normalt dagligt.
GONAL-f is usually given every day.
GONAL-f kan gives som daglige injektioner.
GONAL-f may be given as a course of daily injections.
GONAL-f leveres i pakninger med 1 hætteglas med pulver samt 1 hætteglas med solvens.
GONAL-f is supplied in packs of 1 vial of powder with 1 vial of solvent.
GONAL-f leveres i pakninger med 1 hætteglas med pulver, 1 fyldt injektionssprøjte med solvens samt 15 sprøjter til engangsbrug afmærket med internationale enheder (IE FSH).
GONAL-f is supplied in packs of 1 vial of powder with 1 pre-filled syringe of solvent and 15 disposable syringes for administration graduated in International Units (IU FSH).
GONAL-f leveres i pakninger med 1 hætteglas med pulver, 1 fyldt injektionssprøjte med solvens samt 4 sprøjter til engangsbrug afmærket med internationale enheder (IE FSH).
GONAL-f is supplied in packs of 1 vial of powder with 1 pre-filled syringe of solvent and 4 disposable syringes for administration graduated in International Units (IU FSH).
GONAL-f leveres i pakninger med 1 hætteglas med pulver, 1 fyldt injektionssprøjte med solvens samt 6 sprøjter til engangsbrug afmærket med internationale enheder (IE FSH).
GONAL-f is supplied in packs of 1 vial of powder with 1 pre-filled syringe of solvent and 6 disposable syringes for administration graduated in International Units (IU FSH).
GONAL-f leveres i pakninger med 1, 5, 10 hætteglas med pulver samt det tilsvarende antal fyldte injektionssprøjter med solvens.
GONAL-f is supplied in packs of 1, 5, 10 vials of powder with the corresponding number of solvent in pre-filled syringes.
GONAL-f leveres som en klar, farveløs injektionsvæske, opløsning i fyldt pen.
GONAL-f is presented as a clear, colourless liquid for injection in a pre-filled pen.
GONAL-f leveres som et pulver og solvens, som bruges til at tilberede en injektionsvæske, opløsning.
GONAL-f is presented as a powder and solvent for solution which are used to prepare a solution for injection.
GONAL-f leveres som et pulver og solvens, som bruges til at tilberede en injektionsvæske, opløsning.
GONAL-f is presented as a powder and solvent which are used to prepare a solution for injection.
GONAL-f og GnRH-agonister gives dernæst begge, indtil dine follikler udvikler sig som ønsket.
The GONAL-f and GnRH agonist are then both given until your follicles develop as desired.
GONAL-f sammen med en luteiniserende hormon (LH) opløsning anbefales til stimulation af follikeludvikling hos kvinder med svær mangel af LH og FSH.
GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency.
GONAL-f, i kombination med LH, er desuden blevet undersøgt hos 38 kvinder med svær LH- og FSH- mangel og, i kombination med hGC, hos 19 mænd med hypogonadotropisk hypogonadisme.
GONAL-f, in combination with LH, has also been studied in 38 women with severe LH and FSH deficiency, and in combination with hCG in 19 men with hypogonadotrophic hypogonadism.
GONAL-f-behandling fører sjældent til alvorlig OHSS, medmindre medicinen man anvender for at inducere afsluttende follikelmodning (indeholdende humant choriongonadotropin - hCG), er indgivet.
GONAL-f treatment seldom causes severe OHSS unless the medicine that is used for final follicular maturation (containing human Chorionic Gonadotropin, hCG) is administered.
GONAL-f-dosis kan øges, afhængigt af den virkning, du opnår.
GONAL-f dose may be increased, depending on your response.
GONAL-f’s sikkerhed og virkning hos ældre patienter er ikke klarlagt.
Safety and effectiveness of GONAL-f in elderly patients have not been established.
Gonazon 18,5 mg implantat til hund
Gonazon 18.5 mg implant for dogs
Gonazon indeholder azagly-nafarelin, som er en analog af et naturligt hormon kaldet gonadotrophinfrigørende hormon (GnRH).
Gonazon contains azagly-nafarelin, which is an analogue of a natural hormone called gonadotrophin- releasing hormone (GnRH).
Gonazon solvens til injektionsvæske, opløsning til laks af hunkøn.
Gonazon concentrate for solution for injection of female salmonid fish
Gonazon, koncentrat til injektionsvæske, opløsning til laks af hunkøn.
Gonazon concentrate for solution for injection of female salmonid fish
GORD- diagnosen i disse studier er baseret på endoskopisk vurdering, med undtagelse af et enkelt studie, hvor inkluderingen af patienter alene var baseret på symptomatologi.
GORD diagnosis in these studies was based on endoscopic assessment, with the exception of one study in which the inclusion of the patients was based on symptomatology alone.
gp .
ritonavir.
GP IIb/IIIa- inhibitor (N=2.882)
GP IIb/IIIa inhibitor (N=2,882)
GP IIb/IIIa- inhibitor (N=3.008)
GP IIb/IIIa inhibitor (N=3,008)
gp-hæmning)
inhibition)
gp-substrat), simvastatin (CYP3A4-substrat), de aktive stoffer i et oralt kontraceptivum af kombinationstypen (ethinylestradiol og norgestimat), diltiazem eller ketoconazol.
P-gp substrate), simvastatin (a CYP3A4 substrate), the active components of a combined oral contraceptive (ethinylestradiol and norgestimate), diltiazem or ketoconazole.
gp.
dasabuvir
GPIIb/IIIa-hæmmere var kun tilladt som redningsbehandling og blev anvendt til 2,9 % af patienterne.
GPIIb/IIIa inhibitors were permitted for bailout use only and were used in 2.9% of patients.
Grad (CTC-AE)*
Grade (CTC-AE)
Grad 1 (inkl. ikke
Grade1 (includes grade
Grad 1 (inklusiv
Grade1 (includes grade
Grad 1 (inklusiv grader,
Grade1 (includes grade
Grad 1 (inklusiv grader, der
Grade1 (includes grade
Grad 1 (smertefri ulcerationer, erytem eller let ømhed)
Grade 1 (painless ulcers, erythema, or mild soreness)
Grad 1 eller grad 2 (acceptabel)
Grade 1 or Grade 2 (tolerable)
Grad 1 hånd- og fodsyndrom defineres som følelsesløshed, dysæstesi/paræstesi, prikken, hævelse eller erytem uden smerter af hænderne og/eller fødderne og/eller ubehag der ikke påvirker patienternes daglige aktiviteter.
Grade 1 hand- foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient’s normal activities.